

10/528808

METHOD OF ENHANCING PROLIFERATION AND/OR HEMATOPOIETIC DIFFERENTIATION OF STEM CELLS

BACKGROUND OF THE INVENTION

[001] Chemo- and radiation therapies cause dramatic reductions in blood cell populations in cancer patients. At least 500,000 cancer patients undergo chemotherapy and radiation therapy in the US and Europe each year and another 200,000 in Japan. Bone marrow transplantation therapy of value in aplastic anemia, primary immunodeficiency and acute leukemia (following total body irradiation) is becoming more widely practiced by the medical community. At least 15,000 Americans have bone marrow transplants each year. Other diseases can cause a reduction in entire or selected blood cell lineages. Examples of these conditions include anemia (including macrocytic and aplastic anemia); thrombocytopenia; hypoplasia; immune (autoimmune) thrombocytopenic purpura (ITP); and HIV induced ITP.

[002] Pharmaceutical products are needed which are able to enhance reconstitution of blood cell populations of these patients.

SUMMARY OF THE INVENTION

[003] The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a *cdx* in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous *cdx* protein to the cell, or by introduction into the cell of a genetic construct encoding a *cdx*. The *cdx* is selected from the *cdx* family and includes *cdx1*, *cdx2*, or *cdx4*. The *cdx* may be a wild type

protein appropriate for the species from which the cells are derived, or a mutant form of the protein.

BRIEF DESCRIPTION OF THE DRAWINGS

[004] Figures 1 – 5 show that *cdx4* alters *hox* gene expression in zebrafish and mouse cells and induces blood development in embryoid bodies.

[005] Figure 1 shows effect of *cdx4* and *HoxB4* overexpression on hematopoietic progenitors derived from embryoid bodies (EBs). Colony forming units scored are macrophage (Mac), megakaryocytes and mixed lineage (Meg-mix), granulocyte, macrophage (GM), and granulocyte, macrophage, megakaryocyte (GEMM). Photographs of representative colonies are shown below the graph.

[006] Figure 2 shows quantitative PCR analysis of the expression of selected *HoxA*, *HoxB*, and *HoxC* cluster genes in EBs overexpressing *cdx4*.

[007] Figure 3 shows RT-PCR analysis of *cdx4* expression during EB development.

[008] Figure 4 shows the effect of *cdx4* overexpression on hematopoietic development during different stages of EB development using tetracycline-inducible murine embryonic stem cell lines. *cdx4* expression was induced by the addition of doxycycline between the days indicated below the graph and hematopoietic colony formation was assayed at day 6. The types of colonies scored were the same as above, which the addition of primitive and definitive erythroid colonies (Ery-P and Ery-D, respectively) and mast cell colonies (Mast).

[009] Figure 5 shows a model for the role of *cdx4* in AP patterning and blood development. Signaling molecules such as FGFs, Wnts, and retinoic acid (RA) are known to regulate the expression of *cdx4*, which in turn establishes the correct expression domains of *hox* genes necessary for blood development. In the absence of *cdx4* (right panel), *hox* expression domains are shifted and fewer erythroid cells are formed.

DETAILED DESCRIPTION OF THE INVENTION

[0010] The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells.

The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation, chemotherapy or congenital anemia (*e.g.*, Diamond Blackfan Anemia). The method of the present invention comprises increasing the intracellular level of a *cdx* in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous *cdx* protein to the cell, or by introduction into the cell of a genetic construct encoding a *cdx*. The *cdx* is selected from the *cdx* family and includes *cdx1*, *cdx2*, or *cdx4*. The *cdx* may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein.

[0011] The differentiated and expanded cell populations are useful as a source of hematopoietic stem cells, which may be used in transplantation to restore hematopoietic function to autologous or allogeneic recipients.

[0012] In one embodiment, mammalian stem cells are differentiated to HSCs *in vitro* by increasing the level of *cdx* in the cell. In another embodiment, the number of HSCs in a culture is expanded by increasing the levels of *cdx* in the cell. The intracellular levels of *cdx* may be manipulated by providing exogenous *cdx* protein to the cell, or by introduction into the cell of a genetic construct encoding a *cdx*. The *cdx* may be a wild-type or a mutant form of the protein.

[0013] The term *cdx*, as used herein, is intended to refer to both wild-type and mutant forms of the *cdx* protein family, and to fusion proteins and derivatives thereof. Usually the protein will be of mammalian origin, although the protein from other species may find use. The sequences of many *cdx* proteins are publicly known. Preferably, the mammal is a human and the *cdx* is selected from the group consisting of *cdx1* (GenBank accession number NM_001804; Suh et al., *J. Biol. Chem.* 277:35795 (2002)), *cdx2* (GenBank accession number NM_001265; Yamamoto et al., *Biochem. Biophys. Res. Commun.* 300(4):813 (2003)), or *cdx4* (GenBank accession number NM_005193; Horn et al., *Hum. Mol. Genet.* 4(6),1041-1047 (1995)).

[0014] In one embodiment of the invention, the *cdx* is delivered to the targeted stem cells by introduction of an exogenous nucleic acid expression vector into the cells. Many vectors useful for transferring exogenous genes into target mammalian

cells are available. The vectors may be episomal, *e.g.* plasmids, virus derived vectors such cytomegalovirus, adenovirus, etc., or may be integrated into the target cell genome, through homologous recombination or random integration, *e.g.* retrovirus derived vectors such MMLV, HIV-1, ALV, etc.

[0015] Retrovirus based vectors have been shown to be particularly useful when the target cells are hematopoietic stem cells. For example, see Baum et al. (1996) *J Hematother* 5(4):323-9; Schwarzenberger et al. (1996) *Blood* 87:472-478; Nolta et al. (1996) *P.N.A.S.* 93:2414-2419; and Maze et al. (1996) *P.N.A.S.* 93:206-210.

Lentivirus vectors have also been described for use with hematopoietic stem cells, for example see Mochizuki et al. (1998) *J Virol* 72(11):8873-83. The use of adenovirus based vectors with hematopoietic cells has also been published, see Ogniben and Haas (1998) *Recent Results Cancer Res* 144:86-92.

[0016] Various techniques known in the art may be used to transfect the target cells, *e.g.* electroporation, calcium precipitated DNA, fusion, transfection, lipofection and the like. The particular manner in which the DNA is introduced is not critical to the practice of the invention.

[0017] Combinations of retroviruses and an appropriate packaging line may be used, where the capsid proteins will be functional for infecting the target cells. Usually, the cells and virus will be incubated for at least about 24 hours in the culture medium. Commonly used retroviral vectors are "defective", *i.e.* unable to produce viral proteins required for productive infection. Replication of the vector requires growth in the packaging cell line.

[0018] The host cell specificity of the retrovirus is determined by the envelope protein, *env* (p120). The envelope protein is provided by the packaging cell line. Envelope proteins are of at least three types, ecotropic, amphotropic and xenotropic. Retroviruses packaged with ecotropic envelope protein, *e.g.* MMLV, are capable of infecting most murine and rat cell types. Ecotropic packaging cell lines include BOSC23 (Pear et al. (1993) *P.N.A.S.* 90:8392-8396). Retroviruses bearing amphotropic envelope protein, *e.g.* 4070A (Danos et al, *supra.*), are capable of infecting most mammalian cell types, including human, dog and mouse. Amphotropic packaging cell lines include PA12 (Miller et al. (1985) *Mol. Cell. Biol.* 5:431-437); PA317 (Miller et al. (1986) *Mol. Cell. Biol.* 6:2895-2902) GRIP (Danos et al. (1988)

PNAS 85:6460-6464). Retroviruses packaged with xenotropic envelope protein, *e.g.* AKR env, are capable of infecting most mammalian cell types, except murine cells.

[0019] The sequences at the 5' and 3' termini of the retrovirus are long terminal repeats (LTR). A number of LTR sequences are known in the art and may be used, including the MMLV-LTR; HIV-LTR; AKR-LTR; FIV-LTR; ALV-LTR; etc. Specific sequences may be accessed through public databases. Various modifications of the native LTR sequences are also known. The 5' LTR acts as a strong promoter, driving transcription of the *cdx* gene after integration into a target cell genome. For some uses, however, it is desirable to have a regulatable promoter driving expression. Where such a promoter is included, the promoter function of the LTR will be inactivated. This is accomplished by a deletion of the U3 region in the 3' LTR, including the enhancer repeats and promoter, that is sufficient to inactivate the promoter function. After integration into a target cell genome, there is a rearrangement of the 5' and 3' LTR, resulting in a transcriptionally defective provirus, termed a "self-inactivating vector".

[0020] Suitable inducible promoters are activated in a desired target cell type, either the transfected cell, or progeny thereof. By transcriptional activation, it is intended that transcription will be increased above basal levels in the target cell by at least about 100 fold, more usually by at least about 1000 fold. Various promoters are known that are induced in hematopoietic cell types, *e.g.* IL-2 promoter in T cells, immunoglobulin promoter in B cells, etc.

[0021] In an alternative method, expression vectors that provide for the transient expression in mammalian cells may be used. In general, transient expression involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector and, in turn, synthesizes high levels of a desired polypeptide encoded by the expression vector. Transient expression systems, comprising a suitable expression vector and a host cell, allow for the convenient short term expansion of cells, but do not affect the long term genotype of the cell.

[0022] In some cases it may be desirable to provide exogenous *cdx* protein, rather than transducing the cells with an expression construct. The *cdx* protein may be added

to the culture medium at high levels. Preferably the *cdx* protein is modified so as to increase its transport into the cells. *See*, for example, US 2002/0086383.

[0023] In one embodiment of the invention, tat protein is used to deliver *cdx*. The preferred transport polypeptides are characterized by the presence of the tat basic region amino acid sequence (amino acids 49- 57 of naturally-occurring tat protein); the absence of the tat cysteine- rich region amino acid sequence (amino acids 22-36 of naturally-occurring tat protein) and the absence of the tat exon 2-encoded carboxy-terminal domain (amino acids 73-86 of naturally-occurring tat protein). Transport polypeptides are attached to *cdx* by chemical cross-linking or by genetic fusion, where the *cdx* moiety may be a wild-type or stabilized form. A unique terminal cysteine residue is a preferred means of chemical cross-linking.

[0024] The term stem cell is used herein to refer to a mammalian cell that has the ability both to self-renew, and to generate differentiated progeny (see Morrison et al. (1997) Cell 88:287-298). Generally, stem cells also have one or more of the following properties: an ability to undergo asynchronous, or symmetric replication, that is where the two daughter cells after division can have different phenotypes; extensive self-renewal capacity; capacity for existence in a mitotically quiescent form; and clonal regeneration of all the tissue in which they exist, for example the ability of hematopoietic stem cells to reconstitute all hematopoietic lineages. "Progenitor cells" differ from stem cells in that they typically do not have the extensive self-renewal capacity, and often can only regenerate a subset of the lineages in the tissue from which they derive, for example only lymphoid, or erythroid lineages in a hematopoietic setting.

[0025] Stem cells may be characterized by both the presence of markers associated with specific epitopes identified by antibodies and the absence of certain markers as identified by the lack of binding of specific antibodies. Stem cells may also be identified by functional assays both *in vitro* and *in vivo*, particularly assays relating to the ability of stem cells to give rise to multiple differentiated progeny.

[0026] Stem cells can be derived from a human donor, *e.g.*, pluripotent hematopoietic stem cells, adult somatic stem cells, and the like. Embryonic stem cells may also be used. Stem cells can also be obtained from umbilical cord blood, amniotic fluid, chorionic villus and placenta. *See*, WO03042405.

[0027] Other hematopoietic "progenitor" cells of interest include cells dedicated to lymphoid lineages, *e.g.* immature T cell and B cell populations. The methods of the present invention are useful in expanding selected populations of these cells.

[0028] Purified populations of stem or progenitor cells may be used to initiate the cultures. For example, human hematopoietic stem cells may be positively selected using antibodies specific for CD34, thy-1; or negatively selected using lineage specific markers which may include glycophorin A, CD3, CD24, CD16, CD14, CD38, CD45RA, CD36, CD2, CD19, CD56, CD66a, and CD66b.

[0029] The cells of interest are typically mammalian, where the term refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, laboratory, sports, or pet animals, such as dogs, horses, cats, cows, mice, rats, rabbits, etc. Preferably, the mammal is human.

[0030] The cells which are employed may be fresh, frozen, or have been subject to prior culture. They may be fetal, neonate, adult. Hematopoietic cells may be obtained from fetal liver, bone marrow, blood, particularly G-CSF or GM-CSF mobilized peripheral blood, cord blood or any other conventional source. The manner in which the stem cells are separated from other cells of the hematopoietic or other lineage is not critical to this invention. As described above, a substantially homogeneous population of stem or progenitor cells may be obtained by selective isolation of cells free of markers associated with differentiated cells, while displaying epitopic characteristics associated with the stem cells.

[0031] The stem or progenitor cells are grown *in vitro* in an appropriate liquid nutrient medium. Generally, the seeding level will be at least about 10 cells/ml, more usually at least about 100 cells/ml and generally not more than about 10^5 cells/ml, usually not more than about 10^4 cells/ml.

[0032] Various media are commercially available and may be used, including Ex vivo serum free medium; Dulbecco's Modified Eagle Medium (DMEM), RPMI, Iscove's medium, etc. The medium may be supplemented with serum or with defined additives. Appropriate antibiotics to prevent bacterial growth and other additives, such as pyruvate (0.1-5 mM), glutamine (0.5-5 mM), 2-mercaptoethanol may also be included.

[0033] Culture in serum-free medium is of particular interest. The medium may be any conventional culture medium, generally supplemented with additives such as iron-saturated transferrin, human serum albumin, soy bean lipids, linoleic acid, cholesterol, alpha thioglycerol, crystalline bovine hemin, etc., that allow for the growth of hematopoietic cells.

[0034] Preferably the expansion medium is free of cytokines, particularly cytokines that induce cellular differentiation. The term cytokine may include lymphokines, monokines and growth factors. Included among the cytokines are thrombopoietin (TPO); nerve growth factors; platelet-growth factor; transforming growth factors (TGFs); erythropoietin (EPO); interferons such as interferon- α , β , and γ ; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 γ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12; etc. In some circumstances, proliferative factors that do not induce cellular differentiation may be included in the cultures, *e.g.* c-kit ligand, LIF, and the like.

[0035] Frequently stem cells are isolated from biological sources in a quiescent state. Certain expression vectors, particularly retroviral vectors, do not effectively infect non-cycling cells. Cultures established with these vectors as a source of *cdx* sequences are induced to enter the cell cycle by a short period of time in culture with growth factors. For example, hematopoietic stem cells are induced to divide by culture with c-kit ligand, which may be combined with LIF, IL- 11 and thrombopoietin. After 24 to 72 hours in culture with cytokines, the medium is changed, and the cells are exposed to the retroviral culture, using culture conditions as described above.

[0036] After seeding the culture medium, the culture medium is maintained under conventional conditions for growth of mammalian cells, generally about 37° C and 5% CO₂ in 100% humidified atmosphere. Fresh media may be conveniently replaced, in part, by removing a portion of the media and replacing it with fresh media. Various commercially available systems have been developed for the growth of mammalian cells to provide for removal of adverse metabolic products, replenishment of nutrients, and maintenance of oxygen. By employing these systems, the medium may be maintained as a continuous medium, so that the concentrations of the various ingredients are maintained relatively constant or within a predescribed

range. Such systems can provide for enhanced maintenance and growth of the subject cells using the designated media and additives.

[0037] These cells may find various applications for a wide variety of purposes. The cell populations may be used for screening various additives for their effect on growth and the mature differentiation of the cells. In this manner, compounds which are complementary, agonistic, antagonistic or inactive may be screened, determining the effect of the compound in relationship with one or more of the different cytokines.

[0038] The populations may be employed as grafts for transplantation. For example, hematopoietic cells are used to treat malignancies, bone marrow failure states and congenital metabolic, immunologic and hematologic disorders. Marrow samples may be taken from patients with cancer, and enriched populations of hematopoietic stem cells isolated by means of density centrifugation, counterflow centrifugal elutriation, monoclonal antibody labeling and fluorescence activated cell sorting. The stem cells in this cell population are then expanded *in vitro* and can serve as a graft for autologous marrow transplantation. The graft will be infused after the patient has received curative chemo-radiotherapy.

[0039] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (*e.g.* amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.

[0040] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

EXAMPLES

Introduction

[0041] The formation of blood cells during vertebrate development occurs in successive stages in anatomically distinct sites⁶. In amniotes, the first wave (known

as primitive or embryonic hematopoiesis) originates in the yolk sac blood islands and is characterised by the formation of erythroid and endothelial cells. The coincident onset of both hematopoiesis and vasculogenesis in the yolk sac has led to the hypothesis that both cell types are derived from a common precursor, termed the hemangioblast⁷. In zebrafish, embryonic haematopoiesis occurs in an intra-embryonic location known as the intermediate cell mass (ICM). The ICM develops along the trunk midline by the convergence of bilateral stripes of hematopoietic and vascular precursors. One of the earliest molecular markers of these ICM precursors is the stem cell leukaemia (*scl*) gene, which encodes a basic helix-loop-helix transcription factor^{8,9}. Gene targeting studies in mice have demonstrated that *scl* is necessary for the development of all hematopoietic lineages. In contrast, endothelial cells are present in *scl* null embryos but fail to remodel properly in the yolk sac^{10,11}. Studies in zebrafish have shown that overexpression of *scl* during development is sufficient to induce ectopic blood and vascular cells and these findings have led to the suggestion that *scl* is capable of specifying hemangioblast fate from mesoderm⁸.

[0042] While fate-mapping studies in zebrafish have shown that embryonic blood cells arise from ventral mesoderm of the late blastula^{12,13} the molecular pathways responsible for inducing the early expression of *scl* are largely unknown. In general, posterior tissues of mesodermal origin are derived from ventral mesoderm whereas anterior tissues descend from more dorsal mesoderm. Consistent with this, genes that 'ventralize' the early gastrula embryo, such as the bone morphogenetic proteins (BMPs), induce an expansion of blood and posterior tissues at the expense of more anterior structures such as the head¹⁴. Thus, factors that determine posterior cell fates along the anteroposterior (AP) axis must also be intimately connected with genes that specify ventral fates including blood.

[0043] The establishment of tissues along the AP axis of the embryo is dependent upon the homeobox transcription factors encoded by the *hox* genes¹⁵. Within the genome, these genes are grouped together in clusters (*HoxA*, *HoxB*, *HoxC* and *HoxD*) and are expressed in overlapping domains along the AP axis with their anterior expression limits correlating to their physical order within the cluster. Perturbations in these anterior expression boundaries result in changes in cell fate and this has led to the 'Hox code' hypothesis, in which specific combinations of *Hox* genes are believed to specify tissue identities along the AP axis¹⁵. Despite being held as critical

regulators of embryonic patterning, the effects of germline disruptions of *Hox* genes in the mouse are largely restricted to the axial skeleton, neural crest, central nervous system, and limbs^{3,15}. The relatively mild phenotypes of single *Hox* gene knockouts in mice can be explained by extensive functional redundancy between paralogous genes within each cluster.

[0044] A number of studies have demonstrated that ectopically expressed *hox* genes can influence hematopoietic lineage decisions^{4,5}. For example, overexpression of *HoxA9*, *HoxB4*, and *HoxB7* has been shown to modulate the proliferation/self-renewal of mouse hematopoietic stem cells¹⁶⁻¹⁹. In addition, ectopically expressed *HoxB4* can induce embryonic hematopoietic progenitors to acquire properties characteristic of adult hematopoietic stem cells²⁰. Deregulated *Hox* gene expression is also associated with leukaemic transformation^{4,5}. Overexpression of *HoxA9*^{18,21} or *HoxA10*²² in murine bone marrow ultimately leads to acute myeloid leukaemia (AML) whereas proviral activation of *HoxA7* has been implicated in myeloid leukaemia²³. A subset of human AML is associated with a fusion of the *NUP98* gene, which encodes a component of the nuclear pore complex, to a number of different *HOX* genes including *HOXA9*²⁴. Translocations involving the *MLL* gene, a homologue of *MLL* that is required for the maintenance of *HOX* gene expression, have also been implicated in certain human leukaemias²⁵.

[0045] In this study we have characterised the zebrafish *kugelig* (*kkg*) mutant, which exhibits reduced *scl* expression, severe anemia, and a shortened AP axis. We identify the *kkg* locus as the *caudal*-related homeobox gene *cdx4* and show that the defect in erythropoiesis is associated with aberrant *hox* gene expression. Overexpressing *scl* in *kkg* mutants fails to rescue blood development indicating that the specification of hematopoietic cell fate is dependent upon *cdx4* function. In contrast, erythropoiesis in *kkg* mutants can be robustly rescued by overexpressing *hoxb7a* and *hoxa9a* but not *hoxb8a*, suggesting that the hematopoietic defects result directly from perturbations in *hox* gene expression. Overexpression of *cdx4* during zebrafish development or in mouse embryonic stem cells induces blood formation and alters *hox* gene expression patterns. Taken together, our findings demonstrate that *cdx4* is both necessary and sufficient for the formation of embryonic blood cells during vertebrate development.

Example 1

Methods

[0046] Computer analysis. The genetic map position of *kkg* was obtained from the Max-Planck-Institut für Entwicklungsbiologie (Tübingen, Germany) website (<http://wwwmap.tuebingen.mpg.de/>). Genomic sequence of the *cdx4* locus was obtained from the Wellcome Trust Sanger Institute website (http://www.sanger.ac.uk/Projects/D_rerio/). RH mapping data was provided by the Children's Hospital Genome Initiative (Boston, MA) website (<http://zfrhmaps.tch.harvard.edu/ZonRHmapper/>). Protein sequence prediction and alignment were performed using DNASTAR software.

[0047] Deletion analysis and genotyping. The following primers to each exon of the *cdx4* gene were used to determine the extent of the *kkg*^{tv205} deletion by PCR: exon one (forward 5'-AGCTCCTTTTGGACTATTAC-3' (SEQ ID NO: 1); reverse 5'-CCAACGTACATGATTTGGAA-3' (SEQ ID NO: 2)), exon two (forward 5'-ATACCTTTTGGAGAAAGAGG-3' (SEQ ID NO: 3); reverse 5'-CCGGTTGATGACGACTGGAC-3' (SEQ ID NO: 4)), exon three (forward 5'-CAAAACGAGAACGAAGGAGA-3' (SEQ ID NO: 5); reverse 5'-ACCTGTCTCTCTGAAAGCCC-3' (SEQ ID NO: 6)), and exon four (forward 5'-TAAGATCTGGTTTCAGAACC-3' (SEQ ID NO: 7); reverse 5'-TGGATGATCCAAGTTCGAGT-3' (SEQ ID NO: 8)). Exon three forward and exon four reverse primers were used to genotype *kkg*^{tv205} embryos. Primers specific to the ESTs fj63c09, fb79h04, *flkl* (fk52c05), fb75e05, chic1 (fj33g02), fc54b04, and fi30c11 were obtained from the WashU Zebrafish Genome Resources Project website (<http://zfish.wustl.edu/>), while primer sequences for the markers z20545 and z11437 were obtained from the Massachusetts General Hospital Zebrafish Server website (<http://zebrafish.mgh.harvard.edu>). 3' rapid amplification of cDNA ends (RACE) was performed using the SMART RACE kit (Clontech), cDNA prepared from 14-15 somite stage *kkg*^{tv205} mutants, and the *cdx4*-specific primer 5'-AGCCTCGGACCTCCAAATTC-3' (SEQ ID NO: 9). PCR products were subcloned in the pGEM-T easy vector (Promega, Madison, WI) and sequenced.

[0048] Electrophoretic mobility shift assays. EMSAs were performed using the Gel Shift Assay System (Promega, Madison, WI) and *in vitro* translated (IVT)

proteins prepared using the TNT SP6 Quick Coupled Transcription/Translation System (Promega, Madison, WI). Double-stranded oligonucleotide probes contained a single consensus *cdx* binding site (5'-GAGAAATTTATATTGT-3' (SEQ ID NO: 10); binding site consensus is underlined) or mutated site (5'-GAGAAATCCATATTGT-3' (SEQ ID NO: 11); mutated nucleotides are underlined).³⁵ S-methionine-labelled IVT *cdx4* (wt) and the F(170)L mutant proteins were resolved on a 10-20% Tris-HCl polyacrylamide gel (Ready Gels, Biorad, Hercules, CA) alongside prestained broad range standards (Biorad) and analysed by autoradiography.

[0049] Fish strains. The *kgg*^{tv205} and *kgg*^{tl240} mutant lines were obtained from the Tübingen stock center (Tübingen, Germany) and exhibit a similar severity of phenotype. Wild-type strains were AB, Tü, and WIK. Fish maintenance, breeding, and embryo staging were performed according to standard procedures.

[0050] Inducible *cdx4* ES cell lines and colony assays. The inducible *cdx4*-targeting plasmid (plox-*cdx4*) was generated by subcloning mouse *cdx4* into the *EcoRI/XbaI* site of the plox vector²⁰. To make the tetracycline-inducible *cdx4* ES cell line, Ainv15 ES cells were electroporated with 20 ug of plox-*cdx4* and 20 ug of pSalk-*Cre*, followed by selection with G418 (400 ug/ml) in ES culture medium. Colonies positive for plox-*cdx4* were confirmed by RT-PCR. The tetracycline-inducible *cdx4* ES cells and EBs were maintained and produced as described previously²⁰. Briefly, day 2 EBs from hanging-drops were harvested and cultured in rotating petri dishes. Doxycycline was added into EB medium for the indicated time periods and then removed by three washes of PBS, followed by ES culture medium. EBs were collected at day 6 by collagenase treatment and plated into Methocult GF M3434 (StemCell Technologies). The colonies were scored 6-9 days later.

[0051] Microinjection. Wild-type and F(170)L mutant *cdx4* cDNAs were subcloned into the expression vector pCS2⁺, linearized with *NotI*, and synthetic mRNA made using the mMessage mMachine kit (Ambion, Austin, TX). Capped RNA was resuspended in sterile water and 500 pl was injected between the one- to four-cell stages at a concentration of 30 ng/μl. Full-length *hoxb6b*, *hoxb7a* *hoxb8a*, and *hoxa9a* were amplified from 5-somite stage cDNA by RT-PCR using forward (*hoxb6b*: 5'-ATGCGAATTCCTCCCATGAGTTCCTATTTCGTCA-3' (SEQ ID NO: 12); *hoxb7a*: 5'-ATGCGAATTCACCATGAGTTCATTGTATTATGCG-3' (SEQ ID

NO: 13); *hoxb8a*: 5'-ATGCGAATTCACCATGAGCTCATATTTTCGTCAAC-3' (SEQ ID NO: 14); *hoxa9a*: 5'-ATGCGAATTCACCATGTCGACATCCGGAGCT-3' (SEQ ID NO: 15); start codon underlined)) and reverse (*hoxb6b*: 5'-GCATCTCGAGCTACATTCTACATGTTATGTAC-3' (SEQ ID NO: 16); *hoxb7a*: 5'-GACTCTCGAGCTACTCATCATCTTCTTCTTC-3' (SEQ ID NO: 17); *hoxb8a*: 5'-GCATCTCGAGCTACATTTGTTTTGCCTTGTC-3' (SEQ ID NO: 18); *hoxa9a*: 5'-GATCTCTAGATTAGTCTTCCTTCGTTTC-3' (SEQ ID NO: 19); stop codon underlined) primers and subcloned (along with *scl*) into pCS2+. Synthetic mRNAs were prepared as above and 500 pl was injected at a concentration of 200, 6 and 2-4 ng/ μ l, for *scl*, *hoxb7a/hoxa9a*, and *hoxb6b/hoxb8a*, respectively. The *cdx4* morpholinos (CGTACATGATTTGGAAGAAACCCT (SEQ ID NO: 20); start codon underlined) were obtained from Gene Tools LLC (Corvallis, OR) and solubilized in 1x Danieau solution (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO₄, 5 mM HEPES, pH 7.6) at a stock concentration of 35 mg/ml. One- to four-cell stage embryos were injected with 1 nl of *cdx4* morpholino or an unrelated control morpholino (provided by Gene Tools LLC) at a concentration of 0.2 mg/ml. Injections were performed on a PLI-100 microinjector (Medical systems corp., NY).

[0052] Mutation analysis by RT-PCR. Total RNA was prepared from *kgg*^{tv205} and *kgg*¹¹²⁴⁰ mutant and wild-type embryos at 24 h.p.f. using established procedures and reverse transcribed using Superscript II RNase H- reverse transcriptase (Invitrogen, Carlsbad, CA). The *cdx4* ORF was amplified using forward (5'-CATGTACGTTGGATACCTTTTGG-3' (SEQ ID NO: 21)) and reverse (5'-TCCACAACCCACGCCTCTTATT-3' (SEQ ID NO: 22)) primers, subcloned into the pGEM-T easy vector (Promega, Madison, WI) and sequenced. Our cDNA sequence of wild-type *cdx4* differs from the published sequence (Genbank accession number NM_131109) by the addition of two cytosine nucleotides at +709-710. These extra nucleotides are also found in the *cdx4* genomic sequence deposited in the Sanger Center database. The resulting frameshift changes the open reading frame of the carboxy terminus to give a predicted protein of 271 residues rather than the published length of 301 residues³². The F(170)L mutation of the *kgg*¹¹²⁴⁰ allele was confirmed by sequencing six independent clones.

[0053] Radiation hybrid mapping. The *cdx4* gene was mapped onto the Goodfellow RH panel by the Children's Hospital Genome Initiative group (Boston,

MA) using the following forward (5'-AGGCGTGGGTTGTGGATTAC-3' (SEQ ID NO: 23)) and reverse (5'-GATACACTCACCACATACAG-3' (SEQ ID NO: 24)) primers. The contig encoding the foreign exon spliced onto exon 2 of *cdx4* in *kbg*¹¹²⁴⁰ mutants was mapped using forward (5'-GTGATCAACAACACGTCC-3' (SEQ ID NO: 25)) and reverse primers (5'-GGAATCTCCTGTCAGCTG-3' (SEQ ID NO: 26)).

[0054] Retroviral expression of *cdx4* in ES cells and quantitative PCR. Murine *cdx4* was subcloned into the retroviral expression vector MSCV-IRES-GFP (pMIG) and retroviruses were generated using an ecotropic packaging vector and co-transfection to make viral supernatants. Embryoid bodies were formed from wild-type (RW4) ES cells by differentiating for 6 days and then definitive haematopoietic cells were enriched using an anti-CD41 magnetic strategy resulting in a 10-fold enrichment of CD41/c-Kit⁺ cells. Approximately one million enriched cells were plated on OP9 monolayers in a 6-well dish and subjected to two rounds of retroviral infection with either GFP only or *cdx4/GFP* retroviral supernatants. After 48 hours, GFP⁺ cells were sorted and were either directly lysed in Trizol (Invitrogen, Carlsbad, CA) for RNA preparation, or were plated in methylcellulose (M3434, StemCell Technologies) and scored for colony types 3-7 days later. Representative colonies were cytospun and stained using Jorvet J-322 Dip Quik, (Jorgensen Laboratories Inc., Loveland, CO). To quantitate the relative level of *Hox* gene mRNA, random hexamer-primed cDNA was prepared from total RNA from either GFP expressing or *cdx4/GFP*-expressing cells. Real time PCR measurements were performed with an ABI Prism 7700 Sequence Detector and dual labeled probes (sequence available on request), with the exception of *HoxB4*, which was quantitated using Sybr green reagents (Applied Biosystems). PCR reactions were performed in triplicate with internal references (*GAPDH*) used to normalize samples. *Hox* expression levels are expressed in arbitrary units (relative to the lowest sample) using the comparative C_T method.

[0055] *In situ* hybridisation and sectioning. *In situ* hybridisation of mouse embryos was performed as previously described⁵⁶. Whole mount *In situ* hybridisation of zebrafish embryos was performed with double staining using the red substrate BCIP-INT. Embryos were fixed overnight in 4% paraformaldehyde, transferred to glycerol, flat-mounted under glass coverslips when possible, and photographed. The following riboprobes were used: *cdx4*, *cxc4*, *flk1*, *fli1*, *gata1*, *globin e3*, *hoxb5a*,

hoxb6b, *hoxb7a*, *hoxb8a*, *hoxa9a*, *myoD*, *par1*, *pax2.1*, *runx1*, *scl*, and *wt1*. Full-length cDNAs of the following *hox* genes were isolated by RT-PCR from 5-somite stage cDNA and subcloned into pCS2+ for riboprobe synthesis: *hoxb4* (forward 5'-ATGCGAATTCACCATGGCCATGAGTTCCTATTTG-3' (SEQ ID NO: 27); reverse 5'-GCATCTCGAGCTATAGACTTGGCGGAGGTCC-3' (SEQ ID NO: 28)), *hoxb8b* (forward 5'-ATGCGAATTCACCATGAGTTCCTACTTCGTC AAT-3' (SEQ ID NO: 29); reverse 5'-GCATCTCGAGCTATTTAGAATTGCTAGAAGC-3' (SEQ ID NO: 30)). Embryos to be sectioned were infiltrated in JB-4 resin, cut at a thickness of 5 μ m, and then counterstained in 0.5% Safranin O before being mounted.

Results

Characterization of the *kkg* mutant

[0056] We found that embryos homozygous for *kugelig* (*kkg*), an autosomal recessive mutation that was initially identified due to tail defects²⁶, exhibit severe anemia within the first day of development. Two *kkg* alleles, *kkg*^{tv205} and *kkg*^{l240}, of equal severity have been isolated²⁶. Although blood cell numbers begin to recover by 5 days post-fertilization (d. p. f.), all mutants die between 7-10 d. p. f. To investigate the haematopoietic defect in *kkg*, we examined the expression of *scl*, *gata1*, and *runx1*. At the 5-somite stage, the bilateral stripes of *scl*⁺ cells are thinner in *kkg*^{tv205} embryos compared to wild-type (wt) controls. In addition, *kkg*^{tv205} mutants show a decreased number of *gata1*⁺ erythroid precursors and a complete absence of *runx1* expression in blood and neuronal cells. Consistent with the neuronal loss of *runx1* expression there are reduced numbers of Rohon-Beard cells at later stages. By 24 hours post-fertilization (h. p. f.), *kkg*^{tv205} mutants have a severe reduction in the number of *globin*-expressing erythroid cells compared to wt siblings. In contrast, normal numbers of *pu.1*⁺ myeloid cells^{27,28} are formed from the cephalic mesoderm in *kkg*^{tv205} embryos. Similarly, markers of definitive hematopoietic lineages, such as *c-myb* and *rag1*, are expressed in *kkg*^{tv205} mutants at 36 h. p. f and 6 d. p. f., respectively. To study the development of the vasculature in the mutant, we examined the expression of the VEGF receptor, *flk1*. At the 10- and 15-somite stages, *kkg*^{tv205} embryos have relatively normal numbers of angioblasts, although their convergence to the midline is delayed. By 24 h. p. f., the vasculature appears well formed in the mutants and the few blood cells that develop circulate normally. The pronephric kidney arises from mesoderm adjacent to the ICM precursors²⁹. In *kkg*^{tv205}

mutants, the expression domains of the pronephric duct markers *pax2.1*³⁰ and *cxc4b*³¹ are shortened, although unlike the *scl* stripes, the width of the *pax2.1* stripe is unaffected. Transcripts for the glomerulus marker *wt1*²⁹, which are normally expressed in mesoderm adjacent to somites one through four, extend from somites one through six in *kkg*^{tv205} embryos suggesting that the *kkg*^{tv205} mutation leads to an expansion of anterior kidney fates at the expense of more posterior fates. Other structures such as the head, notochord, and somites appear grossly normal in *kkg*^{tv205} embryos, although the length of the embryo is shortened compared to wt embryos.

Identification of *cdx4* as the gene defective in *kkg* mutants

[0057] The *kkg* mutation maps to linkage group 14 near a number of candidate genes including *cdx4*³², *smad5*³³, and *wnt8*³⁴. An analysis of the cDNA sequence of *wnt8* and *smad5* from *kkg* mutants did not identify any mutations. *cdx4* belongs to the *caudal* family of homeobox genes that have been implicated in AP patterning³⁵⁻³⁷. Three *caudal* paralogues exist in mammals (*cdx1*, *cdx2*, and *cdx4*) and mouse gene-targeting studies of *cdx1* and *cdx2* (*cdx4* has yet to be targeted) have demonstrated a role for these genes in the AP patterning of the axial skeleton³⁸⁻⁴⁰. In addition, *cdx2*^{+/-} mice develop hamartomatous polyps in the colon that result from a transformation of the intestinal epithelium to a more anterior (gastric) fate^{39,41,42}. Sequence analysis of the *cdx4* gene from *kkg*^{tv240} mutants revealed a T to A transversion in nucleotide +510, changing a conserved F(170) residue in the homeodomain to a leucine. This mutation prevents the protein from binding to a *cdx4* consensus binding site in gel shift experiments. A partial deletion of the *cdx4* gene, and at least one other neighbouring gene (*chic1*), was found in *kkg*^{tv205} mutants. To characterise this deletion in more detail we isolated the *cdx4* transcript in *kkg*^{tv205} mutants by 3' RACE and found that exon 2 had become spliced onto downstream sequence that extended the *cdx4* open reading frame by 11 amino acids (GFSSVFQSQSD-stop (SEQ ID NO. 31)). Radiation hybrid (RH) mapping of this foreign sequence placed it 20 cR away from the *cdx4* locus. This analysis confirms that the *kkg*^{tv205} mutant protein is truncated prior to the homeodomain and indicates that the deletion responsible for the mutation is small (~0.5 cM). To provide further evidence that the *kkg* phenotype is caused by defects in *cdx4*, we injected wt embryos with *cdx4* antisense morpholinos and found that the resulting morphants phenotypically resembled *kkg* embryos.

[0058] We next examined the expression pattern of *cdx4* during development. Transcripts for *cdx4* are first detected in the early gastrula but become restricted to the posterior-most cells during gastrulation and early somitogenesis. Double whole mount *In situ* hybridisation and sectioning at the 3-somite stage revealed that the *cdx4* expression domain initially includes cells in the posterior mesoderm that express *scl*. However, from the 5-somite stage onward the expression domains of *cdx4* and *scl* are largely non-overlapping. Similar expression profiles were found for the mouse orthologues of *cdx4* and *Scl* during early embryogenesis. At the late primitive streak stage (E7.25), *cdx4* transcripts are confined to mesodermal cells of the posterior embryo, the allantois, and the forming yolk sac wall. While *cdx4* is not expressed in the nascent blood islands, its expression domain does partially overlap with *Scl* in mesodermal cells of the posterior primitive streak and the posterior yolk sac. Taken together, these observations are consistent with a conserved, early role for *cdx4* during the specification of haematopoietic fate.

Overexpression of *cdx4* induces ectopic blood cells

[0059] To further explore the function of *cdx4* during embryonic haematopoiesis, we examined the effect of *cdx4* overexpression in wt embryos. Embryos injected with *cdx4* mRNA (7, 15, or 30 pg) display a range of "posteriorised" phenotypes. In contrast, embryos injected with 15 pg of F(170)L mutant mRNA all exhibit a wt morphology (n=60/60 embryos injected; data not shown). The effect of *cdx4* overexpression (15 pg) on blood development was examined at the 5- to 12-somite stages. Surprisingly, 12-20% of the injected embryos showed ectopic *scl* (n=24/118), *gatal* (n=7/59), and *flil* (n=4/26) expression near the midline in a stripe that ran parallel to the endogenous blood precursors. Cross sections revealed that the ectopic *scl*⁺ cells were unilaterally located adjacent to the notochord. The reason for this restricted localization is currently unclear, however the genes induced appear specific to the hematopoietic program as ectopic *flkl* expression was confined to the upper trunk region (n= 11/69), whereas no ectopic expression of *pax2.1* was found (n=0/55). In contrast, 11-22% of the injected embryos exhibited decreased expression of *scl*, *gatal*, *flil*, *flkl*, and *pax2.1*. The disrupted tissue development in these embryos may result from abnormal gastrulation, or the conversion of mesoderm to an extreme posterior fate. To assess the ability of *cdx4* to rescue *kkg*^{tv205} mutants, we injected 15 pg of *cdx4* mRNA and assayed the number of *scl*⁺ and *gatal*⁺ cells at the 5- and 10-

somite stages, respectively. Consistent with *cdx4* being the gene defective in *kgg* mutants, the hematopoietic defects were partially rescued in approximately 80% of injected mutants (n=15/19 mutants for *scl* and n=27/33 mutants for *gata1*).

kgg mutants have abnormal *hox* gene expression

[0060] In a number of metazoans, *caudal* homologues have been implicated in AP patterning by regulating the expression of *hox* genes^{38,43-45}. To investigate *hox* gene expression in *kgg* mutants we examined the expression of selected *hoxb* cluster genes and *hoxa9a*, as many of these *hox* genes are known to affect haematopoiesis⁵. All of the *hox* genes examined (*hoxb4*, *hoxb5a*, *hoxb6b*, *hoxb7a*, *hoxb8a*, *hoxb8b*, and *hoxa9a*) display altered expression patterns in *kgg*^{tv205} embryos. For instance, the mesodermal expression of *hoxb5a* normally includes somites two and three, the notochord, and the tailbud region, but in *kgg*^{tv205} mutants, *hoxb5a* expression is expanded to include somites two to five, is absent from the notochord, and is reduced in the tailbud. In the case of *hoxb6b* and *hoxa9a*, the expression of these *hox* genes is almost absent in *kgg*^{tv205} mutants.

Overexpression of *hox* genes rescues erythropoiesis in *kgg* mutants

[0061] To further understand how the stripe of hematopoietic/vascular precursors is affected by changes in AP patterning, we examined the *scl*⁺ populations in more detail. During normal development, transcripts for *scl* are first detected around the 3-somite stage in stripes of mesoderm adjacent to the future site of somite six. At the 5-somite stage, *de novo* expression of *scl* occurs adjacent to somites one to five. These cells are most likely angioblasts as they express *flkl* but not *gata1*. Transcripts for *flkl* and *gata1* in cells of the posterior *scl*⁺ stripe appear mutually exclusive, suggesting that this stripe is comprised of juxtaposed populations of angioblasts and haematopoietic precursors.

[0062] In *kgg* mutants, there is a preferential loss of *gata1*⁺ hematopoietic cells from the posterior stripe with little effect on the adjacent angioblasts. This blood loss in *kgg* mutants may result, in part, from a posterior shift in the boundary between the anterior (angioblast) and posterior (blood and angioblast) *scl*⁺ populations. In support of this, the expression domains of *hoxb6b*, *hoxb7a*, and *hoxa9a*, which share an anterior expression limit with *gata1*, are significantly reduced in *kgg*^{tv205} mutants as early as the 3-somite stage. In contrast, the *scl*⁺ anterior angioblasts are found rostral

to the *hoxb7a* expression domain but at a similar AP level as *hoxb5a*. Given that *hox* gene overexpression can transform cell fates¹⁵ and that a number of *hox* genes are expressed during mouse yolk sac haematopoiesis⁴⁶, we examined whether overexpression of *hox* paralogues from the 6th, 7th, 8th, or 9th groups were capable of rescuing the blood defect in *kkg*^{tv205} mutants. Mutants injected with 3 pg of *hoxb7a* and *hoxa9a* mRNA displayed an almost complete rescue of *gata1*⁺ blood cells at the 18-somite stage (65%; n=13/20 mutants and 100%; n=18/18, respectively), although the axial and tail defects were not rescued. In contrast, the highest non-toxic dose of *hoxb6b* mRNA (1-2 pg; 64%; n=7/11) led to a small increase in *gata1*⁺ blood cells, whereas the highest non-toxic level of *hoxb8a* mRNA (1-2 pg) failed to rescue the blood defects (n=0/22 mutants; data not shown). Taken together, these findings suggest that the specification of haematopoietic cell fate is dependent upon the proper expression of *hox* genes such *hoxb7a* and *hoxa9a* in the posterior mesoderm and that overexpression of any one of these *cdx4* targets can rescue erythropoiesis in *kkg* mutants.

[0063] To provide further evidence that *cdx4* and *hox* genes function together in a common pathway, we examined whether *cdx4* overexpression (15 pg) could rescue the expression of *hoxb6b*, *hoxb7a*, and *hoxa9a* in *cdx4* morphants. We found a restoration of *hoxb6b*, *hoxb7a*, and *hoxa9a* expression domains in *cdx4*-rescued morphants. Interestingly, approximately 80% of the injected embryos also displayed ectopic *hoxb7a* expression in the forebrain and/or hindbrain regions (n=31/39), thus supporting a role for *cdx4* in the induction of *hox* gene expression.

Overexpression of *scl* fails to rescue erythropoiesis in *kkg* mutants

[0064] In zebrafish, overexpression of *scl* leads to an expansion of hematopoietic cells in the posterior lateral plate mesoderm⁸. We examined whether *scl* overexpression could rescue erythropoiesis in *kkg* mutants. Wild-type embryos injected with *scl* mRNA (100 pg), display an expanded number of *gata1*⁺ erythroid precursors at the 10 somite stage. In contrast, no such expansion in erythroid cell numbers was found in *scl*-injected *kkg* embryos. Given that *cdx4* expression precedes that of *scl* in the posterior mesoderm, our results suggest that the specification of haematopoietic fate by *scl* is dependent on *cdx4*.

cdx4 expands multipotential haematopoietic progenitors derived from murine ES cells

[0065] Several studies have shown that retroviral expression of *Hoxb4* in hematopoietic stem cells or multipotential progenitors enhances the self-renewal/proliferation of these cells^{16,19,47}. To examine whether *cdx4* has a similar activity, we retrovirally transduced embryoid body (EB) hematopoietic cells with *cdx4* and assayed the effect on multilineage hematopoietic colony formation. In this system, *cdx4* induced a pronounced expansion of hematopoietic progenitors, including a 13-fold increase in CFU-GEMM (colony forming unit-granulocyte/erythroid/macrophage/megakaryocyte) colonies and a 11-fold increase in CFU-GM colonies compared to *GFP*-only transduced control cells (Fig. 1). The *cdx4*-mediated expansion of multilineage progenitors and colony size was more potent than that observed with *Hoxb4*, which induced a 9-fold increase in CFU-GEMM (Fig. 1). We next examined changes in the expression of selected *HoxA*, *HoxB*, and *HoxC* cluster genes in the *cdx4*-transduced cells using quantitative PCR. Consistent with the role of *cdx4* as a *Hox* gene regulator, we found widespread alterations in *Hox* expression levels in cells transduced with *cdx4* compared to controls (Fig. 2). Notably, *cdx4* induced a marked increase in the expression of *HoxB4* (30-fold), *HoxB3* (19-fold), *HoxB8* (5-fold) and *HoxA9* (4.1-fold), all of which have been implicated in hematopoietic stem cell or immature progenitor expansion^{18,48,49}. Taken together, these results suggest that *cdx4* can enhance the proliferation of early haematopoietic progenitors by up-regulating the expression of target *Hox* genes.

[0066] In EBs, precursors committed to primitive and definitive hematopoietic fates arise between day 3 and 4 of differentiation⁵⁰. Consistent with our expression analyses *in vivo*, we find endogenous expression of *cdx4* at day 3 and 4 of EB development (Fig. 3). To more closely investigate the time window during EB differentiation in which *cdx4* can enhance multilineage hematopoietic colony formation we engineered ES cells to express *cdx4* under the control of a tetracycline-inducible promoter. A 'pulse' of *cdx4* expression was induced at different intervals during EB differentiation and haematopoietic colony formation was assayed at day 6 (Fig. 4). The strongest effect of *cdx4* overexpression on colony formation was found between day 4 and 5 of EB development with increased multipotent progenitors (CFU-GEMM), CFU-GM, and primitive erythroid colonies compared to uninduced EBs (Fig. 4). These findings are consistent with *cdx4* acting at early stages of

hematopoietic development to expand the number of multipotential progenitor cells and perhaps, hematopoietic stem cells.

Discussion

[0067] Our studies demonstrate that *cdx4* is essential for hematopoietic development during vertebrate embryogenesis. Defects in *cdx4* lead to an early deficit in *scl*-expressing hematopoietic precursors, whereas overexpression of *cdx4* in zebrafish embryos or mouse ES cells induces blood formation. Loss of *cdx4* function is also associated with widespread perturbations in the expression patterns of multiple *hox* genes. Furthermore, ectopic expression of *cdx4* in both zebrafish and mouse cells alters *hox* gene expression. The rescue of blood development in *kkg* mutants by overexpressing specific *hox* genes suggests a pathway in which *cdx4* acts upstream of the *hox* genes to control embryonic blood development.

[0068] Genetic studies in *Drosophila* led to the proposal that *hox* genes function in specific combinations to confer tissue identities along the AP axis^{1,2}. In *kkg* mutants, the expression domains of *hox* genes expressed in the anterior trunk, such as *hoxb4* and *hoxb5a*, are expanded towards the posterior while others such as *hoxb6b*, *hoxb7a* and *hoxa9a* are severely reduced. With regard to the development of ICM precursors, these perturbations in *hox* expression domains appear to cause a posterior shift in the boundary between the anterior endothelial population and the more posterior populations of blood and endothelial cells. In addition, there is an overall reduction in erythroid cell numbers (schematically represented in Fig. 5). The blood defects in *kkg* mutants can be restored to almost wild-type levels by overexpressing *hoxa9a* and *hoxb7a*, whereas *hoxb6b* rescues poorly and *hoxb8a* fails to rescue. These observations suggest that multiple *hox* genes with redundant activities participate in blood development. In support of this redundancy, the targeted disruption of *HoxB6*, *HoxB7*, or *HoxA9* in mice does not block early embryonic haematopoiesis⁵¹⁻⁵³. Similarly, using morpholinos to knock-down multiple *hox* genes we have been unable to find single or combinations of *hox* genes that are required for blood formation during zebrafish development. However, there are technical limitations to this approach as non-specific toxicity makes it difficult to inject more than three morpholinos simultaneously.

[0069] Our finding that *scl* overexpression fails to rescue blood development in *kkg* mutants suggests that the *cdx4-hox* pathway may be required to make the posterior lateral plate mesoderm competent to respond to factors that specify haematopoietic fate. In addition to *scl*, these factors are likely to include other molecules such as BMPs, as we have found that enhancing BMP signalling also fails to rescue the blood defect in *kkg* mutants. A role for *hox* genes as 'competence' factors during blood development may explain the restricted localisation of ectopic blood cells induced by *cdx4* overexpression. Rather than being distributed throughout the embryo, the ectopic blood forms a stripe near the midline that is parallel to the endogenous stripes of hematopoietic precursors. The parallel nature of the *cdx4*-induced blood cells suggests that the genes responsible for patterning the endogenous stripes may also be responsible for restricting the localisation of the ectopic blood. In this model, *cdx4* overexpression would induce a combination of *hox* genes that renders the injected cells competent to respond to other pathways acting upstream of *scl*. The spatial localisation of these signals and the influence of other patterning factors would then account for the restricted stripe of *cdx4*-induced blood.

[0070] Our results have implications for the concept of the hemangioblast, a putative bipotential cell that is thought to express *scl* and give rise to both blood and vascular lineages *in vivo*⁵⁴. *kkg* mutants display a reduced number of *scl*⁺ cells with a selective loss of blood but not angioblasts. This finding suggests that if hemangioblasts exist *in vivo* then they must arise prior to the onset of *scl* expression and that *cdx4* is necessary for this putative population to differentiate into an *scl*⁺ hematopoietic precursor. Alternatively, the blood and vascular lineages may arise independently from the posterior mesoderm with *cdx4* being required solely for the specification of hematopoietic fate. Either model does not rule out the possibility that early *scl*⁺ cells still retain the plasticity to form both blood and vascular lineages if transplanted or cultured in a suitable environment.

[0071] Our experiments support a conserved role for *cdx4* in the formation of hematopoietic cells during vertebrate embryogenesis. Like the zebrafish orthologue, mouse *cdx4* expression overlaps with *scl* in posterior regions of the conceptus. In addition, *cdx4* transcripts are enriched in the Rhodamine-123 low fraction of adult mouse bone marrow, which contains the long term repopulating stem cell (Ihor Lemischka pers. comm.). Overexpression of *cdx4* in EBs promotes the formation of

multilineage progenitors and alters the expression of multiple *Hox* genes. The induction of hematopoietic progenitors by *cdx4* is similar to that seen with *HoxB4* overexpression. Furthermore, *cdx4* is able to upregulate the expression of *HoxB4* in EBs, raising the possibility that *HoxB4* mediates the effect of *cdx4* on multilineage progenitor expansion. Given that *HoxB4* can also confer upon primitive progenitors the ability to engraft lethally irradiated adults²⁰, it will be interesting to examine the long-term, multilineage potential of *cdx4*-expressing progenitors in this assay. Unlike *HoxB4*, overexpression of *cdx4* in EBs leads to significantly more CFU-GM colonies compared to the control. This difference may result from other *Hox* genes, or combinations of *Hox* genes, that are induced by *cdx4*.

[0072] Deregulated expression of *Hox* genes by retroviral activation, chromosomal translocation, or upregulation as a result of mutations in upstream activators have all been implicated in leukaemic transformation⁵. The function of *cdx* genes as transcriptional regulators of *hox* genes raises the possibility that this family may also participate in leukaemogenesis. In support of this, a fusion of *CDX2* to *TEL/ETV6*, a gene frequently rearranged in hematological malignancies, has been found in a patient with acute myeloid leukaemia⁵⁵. *CDX2* expression, which is not normally found in hematopoietic cells, was also observed in a case of leukaemia lacking the translocation, suggesting that ectopic expression of *CDX2* can also occur by other mechanisms⁵⁵. The challenge for future studies will be to better understand how *hox* genes downstream of *cdx* genes regulate commitment to a hematopoietic fate and participate in leukaemia.

Example 2

[0073] Injection of *cdx2* morpholinos into *kugelig/cdx4* mutants (resulting in *cdx2* and *cdx4* deficient embryos) results in a complete absence of *gatal*⁺ erythroid precursors and a more severe shortening of the embryonic axis at the 10 somite stage. In contrast, vascular progenitors and kidney duct precursors appear to be little, or unaffected, compared to *kkg* single mutants. Embryos deficient in just *cdx2* display normal blood development. Expression of *cdx2* and *cdx4* overlaps during gastrulation and early somite formation at the time that hematopoietic cells arise during embryogenesis. Taken together, these findings suggest that *cdx2* and *cdx4* act redundantly during development to control the formation of blood cells.

REFERENCES

[0074] The references cited below and incorporated throughout the application are incorporated herein by reference.

1. Lewis, E. A gene complex controlling segmentation in *Drosophila*. *Nature* 276, 565-570 (1978).
2. Struhl, G. Genes controlling segmental specification in *Drosophila* thorax. *Proc. Natl. Acad. Sci. USA* 79, 7380-7384 (1982).
3. Hunt, P. & Krumlauf, R. Deciphering the Hox code: clues to patterning branchial regions of the head. *Cell* 66, 1075-1078 (1991).
4. Buske, C. & Humphries, R. K. Homeobox genes in leukemogenesis. *Int. J. Hematol.* 71, 301-308 (2000).
5. Owens, B. M. & Hawley, R. G. HOX and Non-Hox Homeobox Genes in Leukemic Hematopoiesis. *Stem Cells* 20, 364-379 (2002).
6. Galloway, J. L. & Zon, L. I. Ontogeny of hematopoiesis: examining the emergence of hematopoietic cells in the vertebrate embryo. *Curr. Top. Dev. Biol.* 53, 139-158 (2003).
7. Choi, K., Kennedy, M., Kazarov, A., Papadimitriou, J. C. & Keller, G. A common precursor for hematopoietic and endothelial cells. *Development* 125, 725-732 (1998).
8. Gering, M., Rodaway, A. R. F., Göttgens, B., Patient, R. K. & Green, A. R. The SCL gene specifies haemangioblast development from early mesoderm. *EMBO J.* 17, 4029-4045 (1998).
9. Liao, E. C. et al. SCL/Tal-1 transcription factor acts downstream of cloche to specify hematopoietic and vascular progenitors in zebrafish. *Genes Dev.* 12, 621-6 (1998).
10. Shivdasani, R. A., Mayer, E. L. & Orkin, S. H. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. *Nature* 373, 432-434 (1995).
11. Robb, L. et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. *Proc. Natl Acad. Sci. U. S. A.* 92, 7075-7079 (1995).

12. Kimmel, C. B. Origin and organization of the zebrafish fate map. *Development* 108, 581-594 (1990).
13. Warga, R. M. & Nusslein-Volhard, C. Origin and development of the zebrafish endoderm. *Development* 126, 827-838 (1999).
14. Hammerschmidt, M., Serbedzija, G. N. & McMahon, A. P. Genetic analysis of dorsoventral pattern formation in the zebrafish: requirement of a BMP-like ventralizing activity and its dorsal repressor. *Genes Dev.* 10, 2452-61 (1996).
15. Krumlauf, R. Hox genes in vertebrate development. *Cell* 78, 191-201 (1994).
16. Sauvageau, G. et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. *Genes Dev.* 9, 1753-1765 (1995).
17. Care, A. et al. Enforced expression of HOXB7 promotes hematopoietic stem cell proliferation and myeloid-restricted progenitor differentiation. *Oncogene* 18, 1993-2001 (1999).
18. Thorsteinsdottir, U. et al. Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion. *Blood* 99, 121-129 (2002).
19. Antonchuk, J., Sauvageau, G. & Humphries, R. K. HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. *Cell* 109, 39-45 (2002).
20. Kyba, M., Perlingeiro, R. C. & Daley, G. Q. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. *Cell* 109, 29-37 (2002).
21. Kroon, E. et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. *EMBO J.* 17, 3714-3725 (1998).
22. Thorsteinsdottir, U. et al. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. *Mol. Cell Biol.* 17, 495-505 (1997).
23. Nakamura, T., Largaespada, D. A., Shaughnessy, J. D. J., Jenkins, N. A. & Copeland, N. G. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. *Nat. Genet.* 12, 149-153 (1996).
24. Lam, D. H. & Aplan, P. D. NUP98 gene fusions in hematologic malignancies. *Leukemia* 15, 1689-1695 (2001).

25. Ziemins-van der Poel, S. et al. Identification of a gene, *MLL*, that spans the breakpoint in 11q23 translocations associated with human leukemias. *Proc. Natl Acad. Sci. U. S. A.* 88, 10735-10739 (1991).
26. Hammerschmidt, M. et al. Mutations affecting morphogenesis during gastrulation and tail formation in the zebrafish, *Danio rerio*. *Development* 123, 143-51 (1996).
27. Bennett, C. M. et al. Myelopoiesis in the zebrafish, *Danio rerio*. *Blood* 98, 643-651 (2001).
28. Lieschke, G. J., Oates, A. C., Crowhurst, M. O., Ward, A. C. & Layton, J. E. Morphologic and functional characterization of granulocytes and macrophages in embryonic and adult zebrafish. *Blood* 98, 3087-3096 (2001).
29. Serluca, F. C. & Fishman, M. C. Pre-pattern in the pronephric kidney field of zebrafish. *Development* 128, 2233-2241 (2001).
30. Krauss, S., Johansen, T., Korzh, V. & Fjose, A. Expression of the zebrafish paired box gene *pax[zf-b]* during early neurogenesis. *Development* 113, 1193-1206 (1991).
31. Chong, S. W., Emelyanov, A., Gong, Z. & Korzh, V. Expression pattern of two zebrafish genes, *cxc4a* and *cxc4b*. *Mech Dev.* 109, 347-354 (2001).
32. Joly, J. S. et al. Expression of a zebrafish caudal homeobox gene correlates with the establishment of posterior cell lineages at gastrulation. *Differentiation* 50, 75-87 (1992).
33. Hild, M. et al. The *smad5* mutation *somitabun* blocks *Bmp2b* signaling during early dorsoventral patterning of the zebrafish embryo. *Development* 126, 2149-2159 (1999).
34. Postlethwait, J. H. et al. Vertebrate genome evolution and the zebrafish gene map. *Nat. Genet.* 18, 345-9 (1998).
35. Mlodzik, M., Fjose, A. & Gehring, W. J. Isolation of *caudal*, a *Drosophila* homeo box-containing gene with maternal expression whose transcripts form a concentration gradient at the pre-blastoderm stage. *EMBO J.* 4, 2961-2969 (1985).
36. Katsuyama, Y., Sato, Y., Wada, S. & Saiga, H. Ascidian tail formation requires caudal function. *Dev. Biol.* 213, 257-268 (1999).

37. Edgar, L. G., Carr, S., Wang, H. & Wood, W. B. Zygotic expression of the caudal homolog *pal-1* is required for posterior patterning in *Caenorhabditis elegans* embryogenesis. *Dev. Biol.* 229, 71-88 (2001).
38. Subramanian, V., Meyer, B. I. & Gruss, P. Disruption of the murine homeobox gene *cdx1* affects axial skeletal identities by altering the mesodermal expression domains of Hox genes. *Cell* 83, 641-653 (1995).
39. Chawengsaksophak, K., James, R., Hammond, V. E., Kontgen, F. & Beck, F. Homeosis and intestinal tumours in *cdx2* mutant mice. *Nature* 386, 84-87 (1997).
40. van den Akker, E. et al. *cdx1* and *cdx2* have overlapping functions in anteroposterior patterning and posterior axis elongation. *Development* 129, 2181-2193 (2002).
41. Beck, F., Chawengsaksophak, K., Waring, P., Playford, R. J. & Furness, J. B. Reprogramming of intestinal differentiation and intercalary regeneration in *cdx2* mutant mice. *Proc. Natl. Acad. Sci. U. S. A.* 96, 7318-7323 (1999).
42. Tamai, Y. et al. Colonic hamartoma development by anomalous duplication in *cdx2* knockout mice. *Cancer Res.* 59, 2965-2970 (1999).
43. Charité, J. et al. Transducing positional information to the Hox genes: critical interaction of *cdx* gene products with position-sensitive regulatory elements. *Development* 125, 4349-4358 (1998).
44. Hunter, C. P., Harris, J. M., Maloof, J. N. & Kenyon, C. Hox gene expression in a single *Caenorhabditis elegans* cell is regulated by a caudal homolog and intercellular signals that inhibit Wnt signaling. *Development* 126, 805-814 (1999).
45. Isaacs, H. V., Pownall, M. E. & Slack, J. M. W. Regulation of Hox gene expression and posterior development by the *Xenopus* caudal homologue *Xcad3*. *EMBO J.* 17, 3413-3427 (1998).
46. McGrath, K. E. & Palis, J. Expression of homeobox genes, including an insulin promoting factor, in the murine yolk sac at the time of hematopoietic initiation. *Mol. Reprod. Dev.* 48, 145-153 (1997).
47. Buske, C. et al. Deregulated expression of *HOXB4* enhances the primitive growth activity of human hematopoietic cells. *Blood* 100, 862-868 (2002).
48. Bjornsson, J. M. et al. Reduced proliferative capacity of hematopoietic stem cells deficient in *hoxb3* and *hoxb4*. *Mol. Cell Biol.* 23, 3872-3883 (2003).

49. Perkins, A. C. & Cory, S. Conditional immortalization of mouse myelomonocytic, megakaryocytic and mast cell progenitors by the Hox-2.4 homeobox gene. *EMBO J.* 12, 3835-3846 (1993).
50. Kennedy, M. et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. *Nature* 386, 488-493 (1997).
51. Chen, F., Greer, J. & Capecchi, M. R. Analysis of Hoxa7/Hoxb7 mutants suggests periodicity in the generation of the different sets of vertebrae. *Mech. Dev.* 77, 49-57 (1998).
52. Kappen, C. Disruption of the homeobox gene Hoxb-6 in mice results in increased numbers of early erythrocyte progenitors. *Am. J. Hematol.* 65, 111-118 (2000).
53. Lawrence, H. J. et al. Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis. *Blood* 89, 1922-1930 (1997).
54. Choi, K. The hemangioblast: a common progenitor of hematopoietic and endothelial cells. *J. Hematother. Stem Cell Res.* 11, 91-101 (2002).
55. Chase, A. et al. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12). *Blood* 93, 1025-1031 (1999).
56. Kingsley, P. D. et al. Subtractive hybridization reveals tissue-specific expression of ahnak during embryonic development. *Dev. Growth Diff.* 43, 133-143 (2001).

[0075] The present invention has been described in terms of particular embodiments found or proposed by the present inventor to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the present disclosure, numerous modifications and changes can be made in the particular embodiments exemplified without departing from the intended scope of the invention. For example, due to codon redundancy, changes can be made in the underlying DNA sequence without affecting the protein sequence. Moreover, due to biological functional equivalency considerations, changes can be made in protein structure without affecting the biological action in kind or amount. All such modifications are intended to be included within the scope of the appended claims.